Skip to main content
SpringerLink
Log in

Prevention of venous thromboembolism in acutely ill medical patients after the results of recent trials with the new oral anticoagulants

  • IM - REVIEW
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Venous thromboembolism (VTE) is a common potentially life-threatening complication in acutely ill medical patients; over 70 % of the fatal episodes of pulmonary embolism during hospitalization occur in non-surgical patients. In the absence of thromboprophylaxis, the incidence of venographically detected deep vein thrombosis is about 15 % in medical patients. Several trials and meta-analyses have clearly demonstrated the prophylactic role of unfractionated heparin, low molecular weight heparin and fondaparinux. Although over the past few years the knowledge of epidemiology, clinical features and prophylaxis in medical patients has significantly improved, there remain a number of controversial areas that require further investigation. Newer VTE risk assessment models have been proposed to select high risk hospitalized medical patients, but they still require external validation; scarce data are available to stratify patients to identify their individual bleeding risk. The optimal duration of thromboprophylaxis in medical patients is still a matter of debate; currently, extended prophylaxis after discharge is not recommended, but it may be required for subgroup of patients with persistently high VTE risk and a negligible risk of bleeding. Based on the results of recent studies, the new oral anticoagulants appear to have a very limited role, if any. However, a better risk stratification of patients who have a persistently increased risk of VTE is warranted to improve the risk to benefit profile of any anticoagulant drug to be used in this setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Imberti D, Prisco D (2005) Venous thromboembolism prophylaxis in medical patients: future perspectives. Thromb Res 116:365–375

    Article  PubMed  CAS  Google Scholar 

  2. Ageno W, Agnelli G, Imberti D et al (2011) Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry. Intern Emerg Med. doi:10.1007/s11739-011-0644-1

  3. Ageno W, Squizzato A, Garcia D, Imberti D (2006) Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 32:651–658

    Article  PubMed  Google Scholar 

  4. Cohen AT, Combe S, Samama M et al (2004) Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med 164:963–968

    Article  PubMed  Google Scholar 

  5. Kahn SR, Lim W, Dunn AS et al (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl.):e195S–e226S

    PubMed  CAS  Google Scholar 

  6. Lindblad B, Sternby N, Berqvist D (1991) Incidence of venous thromboembolism verified by necroscopy over 30 years. BMJ 302:709–711

    Article  PubMed  CAS  Google Scholar 

  7. Piazza G, Fanikos J, Zayaruzny M et al (2009) Venous thromboembolic events in hospitalised medical patients. Thromb Haemost 102:505–510

    PubMed  CAS  Google Scholar 

  8. Heit JA, Silverstein MD, Mohr DN et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 160:809–815

    Article  PubMed  CAS  Google Scholar 

  9. Samama M (2000) An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 160:3415–3420

    Article  PubMed  CAS  Google Scholar 

  10. Caprini JA, Arcelus JI, Reyna JJ (2001) Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Haematol 38(Suppl. 5):12–19

    Article  CAS  Google Scholar 

  11. Ageno W, Spyropoulos AC, Turpie AG (2012) Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thromb Haemost 107:1027–1034

    Article  PubMed  CAS  Google Scholar 

  12. Roth Yelinek B (2012) Venous thromboembolism prophylaxis of acutely ill hospitalized medical patients. Are we under treating our patients? Eur J Intern Med 23:236–239

    Article  PubMed  Google Scholar 

  13. Cohen AT, Tapson VF, Bergmann JF et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387–394

    Article  PubMed  Google Scholar 

  14. Tapson VF, Decousus H, Pini M et al (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 132:936–945

    Article  PubMed  Google Scholar 

  15. Gussoni G, Campanini M, Silingardi M, GEMINI Study Group (2009) In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. Findings from a multicenter, prospective study. Thromb Haemost 101(5):893–901

    PubMed  CAS  Google Scholar 

  16. Samama MM, Cohen AT, Darmon JY et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with Enoxaparin Study Group. N Engl J Med 341:793–800

    Article  PubMed  CAS  Google Scholar 

  17. Leizorovicz A, Cohen AT, Turpie AGG et al (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874–879

    Article  PubMed  CAS  Google Scholar 

  18. Cohen AT, Davidson BL, Gallus AS et al (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332:325–329

    Article  PubMed  CAS  Google Scholar 

  19. Dentali F, Douketis JD, Gianni M et al (2007) Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 146:278–288

    Article  PubMed  Google Scholar 

  20. Kakkar AK, Cimminiello C, Goldhaber SZ et al (2011) Low-Molecular-Weight Heparin and mortalità in acutelly ill medical patients. NEJM 365:2463–2472

    Article  PubMed  CAS  Google Scholar 

  21. Spyropoulos AC, Anderson FA Jr, Fitzgerald G et al (2011) Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140:706–714

    Article  PubMed  Google Scholar 

  22. Barbar S, Noventa F, Rossetto V et al (2010) A risk assessment model for the identification of hospitalized medical patients a risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 8:2450–2457

    Article  PubMed  CAS  Google Scholar 

  23. Decousus H, Tapson VF, Bergmann JF, IMPROVE investigators et al (2011) Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 139:69–79

    Article  PubMed  Google Scholar 

  24. Falciani M, Imberti D, Prisco D (2006) Prophylaxis and treatment of venous thromboembolism in patients with cancer: an update. Intern Emerg Med 1:273–278

    Article  PubMed  Google Scholar 

  25. Mahan CE, Pini M, Spyropoulos AC (2010) Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing. Intern Emerg Med 5:299–306

    Article  PubMed  Google Scholar 

  26. Ageno W (2012) Do medical patients need to receive pharmacologic prophylaxis for the prevention of venous thromboembolism? Intern Emerg Med 7(suppl 3):S189–S192

    Article  PubMed  Google Scholar 

  27. Hull RD, Schellong SM, Tapson VF et al (2010) Extended duration of venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 153:8–18

    Article  PubMed  Google Scholar 

  28. Gussoni G, Campanini M, Silingardi M, GEMINI Study Group (2009) In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. Findings from a multicenter, prospective study. Thromb Haemost 101:893–901

    PubMed  CAS  Google Scholar 

  29. Scannapieco G, Ageno W, Airoldi A, TERSICORE Study Group (2010) Incidence and predictors of venous thromboembolism in post-acute care patients. A prospective cohort study. Thromb Haemost 104:734–740

    Article  PubMed  CAS  Google Scholar 

  30. Turpie AG, Hull RD, Schellong SM, EXCLAIM Investigators (2013) Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study. Stroke 44:249–251

    Article  PubMed  Google Scholar 

  31. Imberti D, Dall’Asta C, Pierfranceschi MG (2009) Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med 4:471–477

    Article  PubMed  Google Scholar 

  32. Imberti D, Gallerani M, Manfredini R (2012) Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. J Thromb Thrombolysis 34:208–213

    Article  PubMed  CAS  Google Scholar 

  33. Goldhaber SZ, Leizorovicz A, Kakkar AK et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167–2177

    Article  PubMed  CAS  Google Scholar 

  34. Cohen AT, Spiro TE, Buller HR et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368:513–523

    Article  PubMed  CAS  Google Scholar 

  35. Portola Pharmaceuticals (2012) Betrixaban: long-acting, oral, direct factor Xa inhibitor [online]. Available from URL: http://www.portola.com/Betrixaban. Accessed 21 Mar 2012

  36. Albertsen IE, Larsen TB, Rasmussen LH et al (2012) Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically III patients: a systematic review and meta-analysis. Drugs 72:1755–1764

    Article  PubMed  CAS  Google Scholar 

  37. Turpie AGG, Bauer KA, Davidson BL et al (2009) A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 101:68–76

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors have no conflict of interest to declare.

Author information

Authors and Affiliations

  1. Internal Medicine Department, Haemostasis and Thrombosis Center, Piacenza Hospital, Via Taverna 49, 29121, Piacenza, Italy

    Davide Imberti & Raffaella Benedetti

  2. Clinical and Experimental Medicine, University of Insubria, Varese, Italy

    Walter Ageno

Authors
  1. Davide Imberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raffaella Benedetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Walter Ageno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Davide Imberti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Imberti, D., Benedetti, R. & Ageno, W. Prevention of venous thromboembolism in acutely ill medical patients after the results of recent trials with the new oral anticoagulants. Intern Emerg Med 8, 667–672 (2013). https://doi.org/10.1007/s11739-013-0979-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-013-0979-x

Keywords

Search

Navigation